Driven by multiparameter fluorescence readouts and the analysis of kinetic responses from biological assay systems, the amount and complexity of high-throughput screening data are constantly increasing. As a consequence, the reduction of data to a simple number, reflecting a percentage activity/inhibition, is no longer an adequate approach because valuable additional information, for example, about compound-or process-induced artifacts, is lost. Time series data such as the transient calcium flux observed after activation of Gq-coupled G protein-coupled receptors (GPCRs), are especially challenging with respect to quantity of data; typically, responses are followed for several minutes. Based on measurements taken on the fluorometric imaging plate reader, the authors have introduced a mathematical model to describe the time traces of cellular calcium fluxes mediated by the activation of GPCRs. The model describes the time series using 13 parameters, reducing the amount of data by 90% while guiding the detection of compound-induced artifacts as well as the selection of compounds for further characterization. (Journal of Biomolecular Screening 2006:511-518) Journal of Biomolecular Screening 11(5); 2006 www.sbsonline.org 515 FIG. 5. Kinetic fingerprint plot (normalized s 1 v. normalized s 0 ) for all wells in agonist confirmation assay. Red = maximum controls; gray = 50% controls; blue = minimum controls; brown = compound wells. Insets A to E show examples of time series data, that is, fluorescence intensity (RFU) versus time(s), for typical wells within the corresponding marked areas (see text for explanation). Interestingly, all compounds representing chemical series marked for follow-up can be found close to the origin (1,1).
INTRODUCTION
A CURRENT CHALLENGE within the high-throughput screening (HTS) data analysis process is to analyze, efficiently, large volumes of primary screening data and extract relevant biological parameters, while simultaneously accounting for effects such as nonspecific interactions or compound artifacts, which would otherwise compromise result integrity. 1, 2 Although all assays can suffer from compound-or processinduced artifacts, the drive toward fluorescence-based assay readouts has undoubtedly accelerated the need for methods to detect compound interference. 3, 4 Among fluorescent-based methods, the measurement of transient calcium fluxes in response to the activation of Gqcoupled G protein-coupled receptors (GPCRs) is the standard technique for the pharmacological characterization of receptors and compounds and is frequently applied in primary screening and to generate a compound structure activity relation for lead development programs. 5, 6 Various assay and technology platforms are commercially available, but for many high-throughput applications across academia and the pharmaceutical industry, the fluorometric imaging plate reader (FLIPR) is the standard instrument for measuring calcium responses. [6] [7] [8] Although the kinetics of the calcium flux contain valuable information related to the biological response or the compound action, the signal description parameters most commonly used in HTS are either the area under the response curve (AUC) or the maximum peak height (PH), which are normalized into percentage-effect values using the control wells. 5 All work published so far invariably refers to 1 of these 2 approaches, and there are no descriptions involving more complete analyses of the time development of FLIPR traces within the primary literature.
Further downstream, a commonly asked question relates to the specificity of the measured response, and the archetypal process for hits from a cell-based HTS needs to establish whether hits are selective for the receptor/pathway under investigation. Within this context, it would be very useful if data derived at the primary screen level could be used in an initial triage of screen actives to designate false positives, selective actives, or nonselective actives.
In this article, we present a novel method for the analysis of time series data that reduces overall data amounts, uses previously discarded information to identify compound-induced artifacts, and assists in the selection of compounds for follow-up.
MATERIALS AND METHODS

Data analysis and reduction
Reduction of the time sequence data was performed with the Evotec Acapella data analysis software. A mathematical model was defined to describe the ascending and descending temporal phases of the transient response. The model chosen fits the temporal sequence in 2 separate segments: a single Gaussian function,
is fitted to the segment showing increasing fluorescence intensity values, and a superposition of 2 Gaussian functions,
, is fitted to the segment showing decreasing fluorescence intensity values. Here, t 0 denotes the time when the maximum fluorescence intensity is observed, a 0 denotes the maximum fluorescence intensity value, and s 0 , s 1 , and s 2 denote typical rise and decay times, respectively. By convention, s 1 is used to denote the faster of the 2 decay components, that is, s 1 < s 2. An additive term accounting for basal fluorescence has been omitted for clarity. Data were also transformed to single-end-point data using a classical approach, that is, determining the maximal peak height of the response from the raw time series values. In general, active agonist compounds give rise to an elevated fluorescence signal. The reverse is the case for active antagonist compounds, which give rise to a reduction in the absolute fluorescence signal. To allow comparison between agonist and antagonist assays and maintain consistency, the following convention was adopted in this study to define the main control well types. The maximum response is 100% agonism in agonist format and 0% antagonism in antagonist format; the minimum response is 0% agonism in agonist format and 100% antagonism in antagonist format.
FLIPR assays
Agonist and antagonists primary screens, against Gq-coupled GPCR targets, were run in a no-wash Ca flux microplate format using a FLIPR-384 readout. [9] [10] [11] The assay setup and robotic system have been described previously. 12 For each screen, in excess of 0.5 million compounds were analyzed at the primary level, and hits were retested for confirmation and selectivity determination according to the schema outlined in Figure 1 .
In the agonist format assay, the number of primary hits was 5238. For both confirmation and selectivity analyses, the putative active compounds were arranged across 20 × 384-well plates. In addition, a further 1962 wells contained DMSO without compound. In the antagonist format, the number of primary hits was 10,459. Confirmation and selectivity assays were run across 40 × 384-well plates, representing 10,459 compound wells and 1942 DMSO without-compound wells. In all cases, intraplate controls included maximum response (8 wells), minimum response (8 wells), and a 50% standard (8 wells).
RESULTS AND DISCUSSION
Within our HTS operations, time series data from the FLIPR 384 present a challenge with respect to the sheer amount of data. Consequently, analysis within HTS has been restricted to simple evaluations using AUC or PH, leaving a more detailed analysis of response curves to the secondary screening scientists. The growth in compound file (we routinely screen up to 2 million compounds in FLIPR-based assays) and the observed number of compound-induced artifacts has driven the search for more intelligent tools for the analysis of time series data. The historic approach, that is, to take false-positive compounds into a 2nd round of confirmation for a more detailed analysis, is also no longer feasible, with hit lists running into thousands of compounds. Also, a lot of artifacts induced by compounds interfering with the assay readout (e.g., autofluorescent compounds) can be subtle and not detectable with setting a simple threshold for the overall signal, but nevertheless, these artifacts reduce valuable resources within our teams. Moreover, extended practical experience, albeit restricted to anecdotal evidence, of Ca 2+ flux format assays within our laboratories 12 the necessary information required to make a preliminary assessment of hit selectivity might also be contained within the observed kinetics of the calcium response. Figure 2 shows a typical FLIPR 384 -derived time series for a control well (full agonist response) and the parameters derived from the use of mathematical modeling as described in the Material and Methods section. The curve has been reduced to 13 key parameters, 4 of which are calculated from the raw data, and the other 9 are fit output parameters. This represents a data compression factor of 10 (compared to a time series of 150 s at a sample frequency of 1 s -1 ), reducing the need for data storage and enhancing data loading and visualization, especially in large-scale HTS applications.
The key descriptors of the temporal development of the response curves are s 0 and s 1 , the characteristic ascent and initial descent times. In the analysis presented here, the s 0 and s 1 times were further normalized on a plate-by-plate basis, to remove any interplate variability. The normalized times are defined as follows: s 0 (norm) = s 0 /(median s 0 of maximum control wells) s 1 (norm) = s 1 /(median s 1 of maximum control wells).
Plots of s 0 (norm) versus s 1 (norm) represent a condensed view of the Ca flux kinetics of each well, in what we have termed a kinetic fingerprint. The fold difference for a compound is calculated by comparing the compound s 0 (or s 1 ) with the median s 0 of maximum control wells. For example, if the compound s 0 is 1 s, and the median s 0 of maximum control wells is 10 s, then the fold difference is 10. Similarly, if the compound s 0 is 100 s and the median s 0 of maximum control wells is 10 s, then the fold difference is again 10. The maximum fold difference is the larger of the s 0 or s 1 fold differences.
The goodness-of-fit statistic, χ 2 , describes the concordance between model fits and instrument data, with lower χ 2 values indicating better model fit (Fig. 3A displays the distribution of χ 2 values for compound and control wells in the agonist confirmation assay as well as values for compounds representing the chemical series chosen for follow-up to illustrate spreads). χ 2 values for all well types in both antagonist and agonist assays are summarized in Figure 3B . The χ 2 values for antagonist assays were typically below 3, the exception being the minimum controls, with χ 2 ∼ 5. This is probably due to the low fluorescence signal (no peak) in this well type. For the same To generate a comparator, we analyzed the data following a standard screening sequence (Fig. 1) using the AUC calculation. This analysis shows that both the agonist and antagonist HTS had significant numbers of active compounds (Fig. 4A, B ) selective for the receptor under investigation. Selective actives were those with >30% effect in the confirmation assay and <30% effect in the selectivity assay. The agonist assay had 3027 compounds active at reconfirmation, of which 2124 were selective. The antagonist assay had 1367 reconfirmed actives, of which 1060 were selective.
Conventional as well as kinetic fingerprint plots represent the superposition of numerous biological, mechanical, and fluidics effects that ultimately give rise to the complex final signal. For example, all methods are susceptible to compound on and off rates, as under typical screening conditions, the data acquisition period is curtailed to allow for reasonable plate read cycle times. However, the s 0 and s 1 fingerprint method allows the screening scientist to identify compounds with unusual kinetics and subject these to a more detailed analysis to determine if this behavior is of genuine interest.
Identification of compounds exhibiting grossly nonstandard kinetics
A kinetic fingerprint of all compound and control well data in the agonist assay is shown in Figure 5 . The maximum and 50% control wells, labeled in red and gray, respectively, are all close to the 1,1 origin, as would be expected for well-defined compounds. Close analysis of the 50% agonist data in Figure  5 data does show 1 well in region A, 2 wells in region E, and a further well between regions B and D. The remaining ∼156 wells are very tightly distributed at the center of region B. The loss of 4 control wells in a 20-plate run of a complex assay such as the FLIPR is entirely consistent with our experience as users of this instrument. It should be noted that the wells in A and E were null responders (activation <10%), probably indicating an issue with control addition. At long, short, and intermediate normalized times, there are characteristic clusters of compounds. Time series data representing typical wells in each cluster are shown in inserts A to E. Within insert B, there is the type of fully defined curve that would be expected from a true biological response. However, inserts C and D are characteristic of camera saturation phenomena, most probably due to fluorescence interference. Insert E shows the effects of significant addition-related artifacts at short times, which can lead to under-or overestimates of the agonist activity. Insert A shows a quenching type effect, indicative of compound-related interference, possible arising from a cell disruption or gross cytotoxic effect.
Although it is possible to identify gross artifacts such as camera saturation effects, as exemplified in regions D and E of Figure 5 , by means of a simple threshold technique (e.g., setting a threshold for the total area under the curve), the real underlying value of the fingerprint method is that it allows for a far more subtle assessment of the different properties within large populations of putative active compounds. For example, the quantum efficiency of an interfering fluorophore may be very low, and consequently, it will not cause camera saturation. This type of compound would not be identified by a simple threshold method, but it would have a characteristic kinetic fingerprint. More important, as indicated in Figure 6B and Figure 7 , biologically relevant information is contained within the fingerprint analysis, which in conventional analysis methods is discarded.
Compared to the tight distribution for the maximum control wells, minimum control wells and many of the compound wells are widely distributed in the fingerprint plots, as would be expected when fitting a superposition of Gaussian functions to what in the case of nonagonists would be a straight line. However, for the active agonist compounds, which are best described by the model and ultimately those of real interest, the distributions are tight and the differences between specific and nonspecific compounds are greater than any variability seen in, for example, the 50% control (compare also scales Fig. 6A, B) .
Kinetic fingerprint analysis for agonist and antagonist approaches
A kinetic fingerprint plot is shown for control wells in the antagonist confirmation assay (Fig. 8A) . As anticipated from the χ 2 results, the s 0 (norm) and s 1 (norm) values for minimum controls are more variable than with the other control well types. In a fingerprint plot of the 1367 compounds active in the antagonist confirmation screen, there is little separation between those compounds designated as selective and those labeled as nonselective/artifact (Fig. 8B) . The kinetic fingerprint analysis for the control wells in the agonist confirmation assay (Fig. 6A) show a similar picture with well-defined distributions for maximum and standard well types and a wide spread for minimum well type. Interestingly, actives in the agonist confirmation screen have distinct differences in kinetic fingerprint between selective compounds and those designated nonselective/ artifact (Fig. 6B) . A subset of the nonselective/artifact compound group forms distinct clusters with shifts in s 0 (norm) and s 1 (norm) away from the 1,1 origin. Representing the agonist data as a cumulative histogram (Fig. 7) shows that ∼92% of the selective actives have both s 0 (norm) and s 1 (norm) within 5-fold of those of the maximum control, whereas only 36% of the nonselective/artifact compounds are within the same 5-fold range.
Using kinetic fingerprints artifacts can be removed, and compounds can be prioritized with the overall reduction on resource and cost needed for follow-up. Especially for agonist assay formats, scientists can use χ 2 values describing the goodness of fit as an initial filter in combination with the comparison of the ascending and descending times characteristic for the responses to known standards, to aid the identification of chemically attractive compounds inducing a "real" biological response mediated by the receptor under investigation. 
CONCLUSIONS
The application of mathematical modeling provides an alternative approach to the analysis of time series data that, although reducing the absolute amount of data for calculations and analysis several-fold, makes better use of the information "hidden" in the kinetics of the biological response.
It should be noted that the purpose underlying the application of models to time series data is not to derive fit parameters that accurately describe the time development of each and every curve in a condensed form, as the variability seen with "real" compounds dictates that a multiplicity of curve-fitting functions would be required. Rather, the intention here is to ensure that the model accurately describes the behavior of wellbehaved controls and standards and then quantifies the degree of similarity or dissimilarity displayed by unknown test compounds.
The parameters derived and calculated from the model provide a fingerprint of the biological response that can be applied to develop an intelligent, rule-based, automated high-throughput analysis, as described previously for HTS data derived from single-molecule spectroscopy-based assays. 1 Inherent in these data is the information relating to compound-and processinduced artifacts, and the approach described enables the scientist to identify and remove false positives at an early stage.
In addition, as outlined for agonist assays, the differences in kinetic fingerprints between selective and nonselective compounds can give new information that, together with structural and physico-chemical property information, can be exploited for a 1st triage of compounds. 
